Actively Recruiting

Age: 0Years - 99Years
All Genders
NCT06225882

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

Led by Hospices Civils de Lyon · Updated on 2024-01-26

100

Participants Needed

7

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by mutation in the AGXT gene encoding the hepatic peroxisomal enzyme AGT. Reduced AGT activity results in increased glyoxylate and oxalate production, causing the formation of kidney stones, nephrocalcinosis and renal failure. Clinical trials of Lumasiran have provided information on the efficacy and safety of Lumasiran in the treatment of primary hyperoxaluria type 1. However, they do not provide data on long-term efficacy, safety and patient management. As part of the post-marketing follow-up of Lumasiran, in agreement with the authorities, this study proposes a retrospective and prospective follow-up over 5 years of pediatrics and adults patients treated in France with a standardized clinical, biological and radiological follow-up. The main objective is to monitor the evolution of PH1 parameters and particularly oxaluria before and after treatment.

CONDITIONS

Official Title

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

Who Can Participate

Age: 0Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient with primary hyperoxaluria type 1 who has been treated with Lumasiran since the beginning of the temporary authorization for use or in post-marketing
Not Eligible

You will not qualify if you...

  • Patient or legal representative opposes participation (for minors)
  • Not covered by social security

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

CHU de Besançon

Besançon, France, 25030

Actively Recruiting

2

Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant

Bron, France, 69500

Actively Recruiting

3

Hopital Edouard Herriot

Lyon, France, 69003

Actively Recruiting

4

AP-HM - Timone Enfants

Marseille, France, 13385

Actively Recruiting

5

Hôpital Européen G. Pompidou

Paris, France, 75015

Actively Recruiting

6

CHU Paris - Hôpital Necker-Enfants Malades

Paris, France, 75743

Actively Recruiting

7

Hôpital Necker, APHP Paris, Service de néphrologie-dialyse, 149 rue de Sèvres

Paris, Île-de-France Region, France, 75015

Actively Recruiting

Loading map...

Research Team

M

Mélissa CLOAREC, Clinical Research Associate

CONTACT

S

Sacha FLAMMIER, Project Manager

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France. | DecenTrialz